AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00971815
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/2 pill pr day first week, then 1 pill pr. day throughout a 3 months treatment period (90-118 ± 7days)
Trial: NCT00503815
Drug: BLI-800
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02829814
Drug: TNX-102 SL Tablet, 2.8 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
Trial: NCT03042819
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin is currently approved for various cancers. Doxorubicin inhibits DNA synthesis and repair by inhibiting topoisomerase II and also by intercalation between base pairs on the DNA helix. These actions result in the blockade of DNA and RNA synthesis and fragmentation of DNA.
Trial: NCT00934362
Drug: Placebo first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mL normal saline x 5 doses over 24 hours, then washout period x 14 days, then lucinactant x 5 doses over 24 hours
Trial: NCT02829814
Drug: Placebo SL Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
Trial: NCT01564576
Drug: Profound neuromuscular blockade (Rocuronium, Rocuronium bromide, sugammadex, Bridion)
RxNorm normalized name: Profender
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium dose will be adjusted to maintain a depth of NMB of zero response to train of four and a post tetanic count of no more than 10 responses. At the end of surgery patients will receive a single bolus dose of 4 mg/kg sugammadex according to ideal body weight + 40%12. Extubation will be performed when train-of-four ratios ≥ 0.9.
Trial: NCT04223219
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~* Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxygen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~* The patients will receive fentanyl infusion at a rate of 1 µg/kg/h and fentanyl bolus 20-40 µg according to patient hemodynamics. (tachycardia: increase of heart rate \>20% of baseline or hypertension: increase of blood pressure \>20% of baseline).~* After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion.
Trial: NCT04223219
Drug: Fentanyl, Propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~* Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance of anesthesia will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxugen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~* The patients will receive fentanyl bolus 20 µg/hr and propofol 20 mg at the time of surgical stimulation and according to patient hemodynamics (repeated as required).~* After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion.
Trial: NCT00528450
Drug: tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02127697
Drug: NVA237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVA237 capsules for inhalation, delivered via Concept1 once daily
Trial: NCT02127697
Drug: Placebo to NVA237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to NVA237 delivered via Concept1 once daily
Trial: NCT00111852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-Match Placebo, intravenous administration.
Trial: NCT03205696
Drug: Antiretrovirals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The antiretroviral (ARV) regimen provided by the clinician must follow DHHS guidelines for antiretroviral naïve adolescents and adults
Trial: NCT02681978
Drug: Standard medical therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
Trial: NCT02668536
Drug: Standard Sunscreen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Areas will be treated with a standard preparation, consisting of padimate O (7%) and oxybenzone (3%) will be used as the control sunscreen.
Trial: NCT03348059
Drug: Direct-acting antiviral therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV patients received direct-acting antiviral treatment for 12 or 24 weeks
Trial: NCT03154411
Drug: ABY-029
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A minimum of 6 and a maximum of 12 adult patients with a diagnosis of primary soft-tissue sarcoma will be enrolled. Initial diagnostic biopsy specimens will be analyzed for EGFR positivity (an EGFR pathology score ≥ 1) by immunohistochemistry following routine diagnostic processing by Pathologist. Patients will be administered a single intravenous dose of ABY-029 1-3 hours before surgery.
Trial: NCT00052117
Drug: 2 NRTIs
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02453711
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily subcutaneous (s.c., under the skin) administration.
Trial: NCT02231359
Drug: Berodual® Respimat® solution for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01319994
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 850mg TDS (12 weeks)
Trial: NCT00632866
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo : 2cp/ day since 24 weeks
Trial: NCT03446040
Drug: rHuPH20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT02093819
Drug: Placebo to BI 416970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single rising doses
Trial: NCT02646566
Drug: APD421
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02646566
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00327197
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be administered oral prednisolone at a dose of 0.5 mg/kg, up to a maximum of 40 mg per day for 14 days.
Trial: NCT01891227
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).
Trial: NCT03586557
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous methylprednisolone 1000mg 3\~5 days and subsequent taper
Trial: NCT01600170
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A substance containing no medication and prescribed or given to reinforce a patient's expectation to get well.
Trial: NCT04268394
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate
Trial: NCT04268394
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin
Trial: NCT04491474
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There will be injection of %0.9 saline to bilaterally great occipital nerve and to bilaterally supraorbital nerve.
Trial: NCT04485026
Drug: Standard of care radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care palliative radiotherapy to symptomatic lesions is permissible. The dose to symptomatic lesions should not exceed 30 Gy in 10 fractions. Brain metastases will be treated with standard of care CNS therapy throughout the study. This may include (but is not limited to) stereotactic radiosurgery, neurosurgical intervention, whole brain radiotherapy
Trial: NCT04516291
Drug: Vupanorsen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.
Trial: NCT04516291
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.
Trial: NCT02561338
Drug: HMS5552
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75mgQD
Trial: NCT02561338
Drug: HMS5552
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mgQD
Trial: NCT02561338
Drug: HMS5552
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mgBID
Trial: NCT02561338
Drug: HMS5552
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75mgBID
Trial: NCT03343002
Drug: fentanyl at 10-15 min before end of surgery
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
Trial: NCT03343002
Drug: fentanyl at end of surgery
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
Trial: NCT01326611
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01438827
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension for Injection, Every 6 weeks for one year
Trial: NCT01318980
Drug: GSK2190915 100mg milled tablet
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taken orally
Trial: NCT01318980
Drug: [14C] radiolabelled GSK2190915 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microtracer solution
Trial: NCT01318980
Drug: GSK2190915 100mg milled tablet administered to the proximal small bowel.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ground half of a 200mg tablet. Administered via Enterion capsule.
Trial: NCT01318980
Drug: GSK2190915 100mg milled tablet administered to the distal small bowel.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ground half of a 200mg tablet. Administered via Enterion capsule.
Trial: NCT01318980
Drug: GSK2190915 100mg enteric-coated tablet.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally
Trial: NCT05993299
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be used as a lymphodepleting chemotherapy.
Trial: NCT02970162
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03991520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is comparable to the anakinra formulation without the active medication - a solution (pH 6.5) containing anhydrous citric acid (1.29 mg), disodium EDTA (0.12 mg), polysorbate 80 (0.70 mg), and sodium chloride (5.48 mg) in water for injection
Trial: NCT03401502
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, b.i.d
Trial: NCT06260462
Drug: dual-release hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets 20-25-30-40 mg/day
Trial: NCT06260462
Drug: Conventional glucocortidois
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets 10-15-20-25-37,5-50-62,5 mg/day
Trial: NCT02029898
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00515268
Drug: GSK256066
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK256066 will be available as dry powder inhaler with dosing strengths of 12.5, 37.5, 50 micrograms per inhalation.
Trial: NCT00515268
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo inhaler.
Trial: NCT00806819
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
Trial: NCT00806819
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
Trial: NCT01317199
Drug: High-dose MPX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomly-assigned participants receive 8 capsules of drug (4000mg MPX) once daily for up to 12 cycles (28 days per cycle).
Trial: NCT01317199
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomly-assigned participants receive 8 capsules once daily of placebo composed of pulverized rice for up to 12 cycles (28 days per cycle).
Trial: NCT00034268
Drug: LY900003
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02314208
Drug: Xenbilox
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01996761
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00829504
Drug: Requip® 0.25 mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 0.25 mg
Trial: NCT02314208
Drug: Tahor
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01185080
Drug: AZD8848
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray solution, intranasal, three times weekly for one month
Trial: NCT01185080
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray solution, intranasal, three times weekly for one month
Trial: NCT01185080
Drug: AZD8848 and placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray solution, intranasal, three times weekly for one month
Trial: NCT02876601
Drug: Placebo (0.9% sodium chloride)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (0.9% sodium chloride) infusion over 2h infusion
Trial: NCT02876601
Drug: Placebo (0.9% sodium chloride bolus)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (0.9% sodium chloride) bolus infusion
Trial: NCT02178137
Drug: Diacerien
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02178137
Drug: Glucosamine/Chondroitin
RxNorm normalized name: RITE AID Glucosamine/Chondroitin 750mg-600mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02178137
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00488098
Drug: GSK372475
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01590888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching capsules administered orally once per day for 26 weeks
Trial: NCT01065077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of placebo during 48h
Trial: NCT00384046
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patch, 300 mcg/day testosterone, patch changed every 3-4 days, 24 weeks
Trial: NCT00384046
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patch, placebo, patch changed every 3-4 days, 24 weeks
Trial: NCT05110118
Drug: LY01008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous injection
Trial: NCT01148979
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisdexamfetamine Dimesylate (Vyvanse)-matched placebo capsules.
Trial: NCT00072982
Drug: borage seed oil
RxNorm normalized name: Borage Seed Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Borage oil 13 capsules divided doses daily for 18 months
Trial: NCT01748162
Drug: Prednisolone IF needed
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02260752
Drug: Medical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment of uterine fibroids with only medications, no procedure or surgery is used
Trial: NCT00538668
Drug: 117Lu-J591
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There will be 9 groups of patients. The first group will receive 20 units of test drug and the 9th group will receive 55 units of the test drug. The exact dose of the test drug will depend upon how many patients have been included in this protocol at the time of patient enrollment. Patients will receive 20-55 units (or millicuries) of radioactivity depending upon patient specific height and weight. The assignment of each patient for a specific dose level is purely based on the sequence of recruitment basis and does not depend on the clinical status of the patient.
Trial: NCT01685515
Drug: Oral Decitabine and Tetrahydrouridine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Decitabine and Oral Tetrahydrouridine (THU) given 1-2 hours apart on 2 consecutive days over 8 weeks
Trial: NCT01685515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain water will be dispensed at a similar volume and in the same containers as study drug. The water placebo has a similar appearance and taste to the study drug, since the study drug is highly diluted in water.
Trial: NCT03653507
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine were administered orally twice daily (bid).
Trial: NCT03653507
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo were administered as a minimum 2-hour IV infusion.
Trial: NCT00554632
Drug: Ethinyl estradiol and norgestimate
RxNorm normalized name: Ethinyl estradiol and norgestimate only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive
Trial: NCT00554632
Drug: Ethinyl estradiol and norelgestromin
RxNorm normalized name: Ethinyl estradiol and norelgestromin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal hormonal contraceptive changed weekly
Trial: NCT01516541
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching dalcetrapib placebo orally daily
Trial: NCT02831101
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To evaluate, in the elderly, the impact of a concomitant administration of sufentanil during a step-wise propofol induction of anaesthesia on the depth of sedation measured using BIS and clinical sedation score.
Trial: NCT02831101
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To evaluate presence or absence of strong opioid (sufentanil) on BIS values in the elderly during propofol induction until the loss of consciousness
Trial: NCT03851562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of physiological saline solution
Trial: NCT02079974
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg pravastatin sodium daily for 3 months
Trial: NCT01732718
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet by mouth daily for 6 weeks
Trial: NCT02273596
Drug: ALXN1840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized oral doses of ALXN1840.
Trial: NCT00583895
Drug: 10% ImCOOH cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twenty patients will receive a hydrophilic cream containing 10% ImCOOH and a placebo cream randomized over both limbs twice daily for 14 days with an additional morning application on Day 15.
Trial: NCT00583895
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five patients will receive placebo cream on both limbs twice daily for 14 days with an additional morning application on Day 15.
Trial: NCT01571518
Drug: late leukostim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy